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SUMMARY
We report the molecular characterization of methicillin-resistant Staphylococcus aureus (MRSA)
with resistance to tigecycline and to daptomycin isolated from intensive-care-unit patients in
Brazil over a 6-month period. Thirty-six isolates (25 from infection sites, 11 from nasal sites)
recovered from 23 patients who presented with MRSA infection during this period were
characterized by pulsed-ﬁeld gel electrophoresis, multilocus sequence typing, staphylococcal
cassette chromosome mec (SCCmec) typing, and antimicrobial susceptibility proﬁling. Ten
isolates from six patients and two isolates from different patients were resistant to tigecycline
and daptomycin, respectively. Eight pulsotypes were identiﬁed and one, type A, accounted for
21 isolates from 12 patients; type A isolates were SCCmecII as were a further nine isolates
of other pulsotypes. All but four of the total isolates were sequence type (ST) 5 or ST105
and classiﬁed as clonal complex (CC) 5; the historically prevalent lineage in Brazil,
ST239-SCCmecIII, was identiﬁed in only three patients. Tigecycline-resistant strains were all
ST105-SCCmecII and two patients were nasally colonized by strains of the same pulsotype found
in infection sites. Two ST5-SCCmecII were daptomycin resistant after 48 h incubation. The origin
and mechanism of these resistant strains remains unknown and further studies are warranted to
determine whether such clones are becoming endemic in Brazilian hospitals and to assess their
impact on infection control practice.
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Methicillin-resistant Staphylococcus aureus (MRSA)
is a major nosocomial pathogen throughout the
world but in Brazil it accounts for more than half of
all S. aureus isolates in most hospitals [1].
Several clones of MRSA have spread globally. The
prevalent clone in Brazil and wider Latin America
[Brazilian epidemic clone (BEC), sequence type
239-staphylococcal cassette chromosome mecIII
(ST239-SCCmecIII)] has been identiﬁed in 19 Brazil-
ian cities, and in 14 different states between 1995 and
1997 [2], although several other international lineages
have also been identiﬁed in Brazil [3].
A wide range of resistance to several antimicrobial
agents is a hallmark of MRSA but most isolates
remain susceptible to vancomycin, teicoplanin and
linezolid and these are the primary drugs of choice
for the treatment of MRSA infections in Brazil [4].
Two new compounds, tigecycline and daptomycin,
were approved for use in Brazil in 2005 and 2008, re-
spectively, for the treatment of complicated skin
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and skin structure infections and intra-abdominal
infections caused by MRSA. Daptomycin is a cyclic
lipopeptide targeting the bacterial cell membrane
and several diverse mechanisms have been implicated
in the development of resistance [5]. Tigecycline, by
contrast, belongs to the class of glycylcyclines which
have a high afﬁnity for the bacterial ribosome and
resistance is apparently linked to overexpression of
an efﬂux pump protein [6].
Two recent surveys of antimicrobial resistance of a
large number of bacterial isolates from Latin America
and worldwide have conﬁrmed an extremely low fre-
quency or complete absence of tigecycline resistance
in S. aureus including MRSA [7, 8]; daptomycin re-
sistance is similarly reported to be uncommon [9].
Tigecycline is not recommended for susceptibility test-
ing of S. aureus by the Clinical and Laboratory Stan-
dards Institute (CLSI) [10], although it is listed by the
European Committee on Antimicrobial Susceptibility
testing (EUCAST) [11]. Since most clinical labora-
tories in Brazil follow the CLSI recommendations,
susceptibility testing is normally restricted to Gram-
negative isolates. The ﬁnding reported here, of a clus-
ter of MRSA isolates with reduced susceptibility to
tigecycline and daptomycin was therefore considered
to be signiﬁcant – warranting further investigation
of the antimicrobial resistance and molecular charac-
teristics of the isolates.
The Rizoleta Tolentino Neves Hospital in Belo
Horizonte city, capital of Minas Gerais state and the
sixth most populous city in Brazil, has 333 beds with
a 30-bed adult intensive care unit (ICU) and a ﬁve-
bed infantile ICU. Twenty-three patients were infected
by MRSA between June and December 2009 yield-
ing 25 isolates from infection sites (blood, soft
tissues, bone, etc.) and 11 nasal colonizing isolates.
All isolates were identiﬁed by the Vitek® 2 system
(bioMérieux, France) and conﬁrmed as MRSA by
mecA PCR and SCCmec element subtyping [12].
Isolates were also screened for Panton–Valentine
leukocidin (PVL) by PCR as described previously [13].
The minimum inhibitory concentration (MIC)
of oxacillin, tigecycline, teicoplanin, quinupristin-
dalfopristin, linezolid, daptomycin and vancomycin
for all isolates was determined by Etest®
(bioMérieux). In addition, the MIC of vancomycin
(Sigma-Aldrich Co., USA), daptomycin (Hospira
Inc., USA) and tigecycline (Pﬁzer Inc., USA) were
also evaluated by the broth microdilution method
and susceptibility breakpoints for vancomycin and
daptomycin were interpreted according to CLSI [10].
Tigecycline interpretive criteria were those established
for staphylococci by EUCAST [11], i.e. MIC 40·5
mg/l indicating susceptibility.
All isolates were screened for heterogenous
vancomycin-intermediate S. aureus (hVISA) pheno-
type by one-point population analysis. Overnight
cultures in brain heart infusion (BHI) broth were
adjusted to 0·5 McFarland turbidity and 100-μl
aliquots were spread onto BHI agar plates containing
4 mg/l vancomycin. The plates were read after 24 h
and 48 h incubation at 37 °C. Isolates were interpreted
as being VISA if more than 1000 colonies grew within
48 h and as hVISA if fewer than 1000 colonies grew.
Isolates recovered from the screening medium were
cultured in BHI broth at 37 °C overnight and cells
were diluted in saline to the 0·5 McFarland standard;
100 μl of this suspension and serial tenfold dilutions
were spread on BHI agar plates with various concen-
trations of vancomycin (0–8mg/l) and colonies were
counted after 48 h at 37 °C.
Isolates were subjected to multilocus sequence
typing (MLST) as previously described [14], and the
resulting sequences of the seven housekeeping genes
were compared to those deposited in the MLST data-
base (http://saureus.mlst.net/site). Pulsed-ﬁeld gel
electrophoresis (PFGE) of SmaI DNA digests was per-
formed and interpreted according to Tenover et al.
[15] and analysed with Bionumerics v. 6.5 software
(Applied Maths, Belgium) using the unweighted
pair-group method with arithmetic mean based on
Dice coefﬁcients. Optimization and tolerance values
were set to 0·5% and 1·25%, respectively. Isolates
were considered to be the same pulsotype if proﬁles
showed greater than 80% similarity with others.
All isolates were resistant to oxacillin and har-
boured the mecA gene. There was universal suscepti-
bility to linezolid, teicoplanin and vancomycin.
Sixteen isolates were classiﬁed as intermediately sus-
ceptible to quinupristin-dalfopristin (from both infec-
tion and carriage sites), and 10 and two isolates,
respectively, were resistant to tigecycline and dapto-
mycin (Fig. 1). The latter daptomycin-resistant iso-
lates (MIC 2mg/l) were isolated from infection sites
of different patients and it is of note that they were
not detected on subculture of microdilution assays
before 48 h incubation although CLSI recommends
reading of plates at 24 h. Six patients harboured
tigecycline-resistant strains, four with single isolates
from infected sites (blood, joint, bone), and two with
three and four isolates from both nasal colonization
and infections.
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Two isolates showed growth on the hVISA screen-
ing assay but were not conﬁrmed as the hVISA pheno-
type on subsequent testing on a range of vancomycin
concentrations by comparison with the positive con-
trol strain Mu3 of MRSA.
PFGE analysis differentiated the 36 isolates into
eight pulsotypes, A–H (Fig. 1). Pulsotype A ac-
counted for 21 (53·8%) isolates from 12 patients and
this type was further discriminated into six subtypes
by cluster analysis within the 80% similarity index.
All pulsotype A isolates were SCCmecII, as were a
further nine isolates of other pulsotypes, and were
allocated to two closely related sequence types ST5
and ST105 of clonal complex (CC) 5 which also ac-
counted for isolates of pulsotypes B and C. Pulsotypes
D and E were also grouped as CC5 lineages, but were
of assorted SCCmec types. Tigecycline-resistant
strains were all of ST105-SCCmecII and distributed
among three pulsotypes from six different patients,
two of whom were colonized by strains of the same
pulsotype as the infecting strain. Strain genotypes
corresponding to international strain lineages were
12 isolates of ST5-SCCmecII (New York/Japan
clone), single isolates of ST5-SCCmecI (Cordobes/
Chilean clone) and ST5-SCCmecIV (paediatric
clone) and three ST239-SCCmecIII isolates (BEC).
None of the isolates harboured the genes encoding
for PVL.
Although this study involves only one Brazilian hos-
pital, the results reﬂect the decline in the prevalence
of the BEC lineage and its replacement by other inter-
national clones, notably CC5 [3]. However, unlike
other studies, we have identiﬁed a signiﬁcant aggra-
vating factor of clonal expansion of CC5 strains resist-
ant to tigecycline but markedly less so to daptomycin.
Indeed, reports of susceptibility studies of large series
of MRSA isolates both within Latin America and
worldwide, have identiﬁed none or very few isolates
to be resistant to tigecycline [7–9]. Therefore the ﬁnd-
ing of almost one-third of isolates from ICU patients
with a MIC of >0·5 mg/l for this drug over just
6 months is strongly suggestive of a nosocomial out-
break within the unit, which to our knowledge has
not been previously reported.
Fig. 1. Dendrogram of the PFGE patterns, clinical source, sequence type and SCCmec element, and antimicrobial
resistance of MRSA study isolates. ST, Sequence type; OX, oxacillin; VA, vancomycin; LZD, linezolid; TIG, tigecycline;
Q-D, quinupristin-dalfopristin; DAP, daptomycin; TE, teicoplanin; R, resistant; I, intermediate level of resistance; S,
susceptible; R*, resistant after 48 h;+ccr4, presence of an extra-SCCmec recombinase 4;+mercury, presence of SCC
mercury.
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The two cases of decreased susceptibility to dapto-
mycin merit comment. Several mechanisms have been
cited for daptomycin resistance but Camargo et al.
[16] observed that a laboratory-generated strain of
S. aureus with reduced susceptibility to daptomycin
in vitro, had an altered membrane and cell wall and
grew more slowly than the parental strain. Here,
daptomycin resistance was detected only after 48 h
of incubation which is consistent with a slower growth
of such strains.
In the present study, molecular typing showed that
at least two patients (nos. 10 and 16, Fig. 1) were ﬁrst
colonized in the nares with tigecycline-resistant strains
prior to their recovery in samples from clinical infec-
tion. This indicates that colonization with these strains
persists and emphasizes the importance and value of
surveillance cultures from patients on entry into the
ICU in order that efﬁcient control management can
be applied by the Infection Control Committee in
the nosocomial environment. Further, this could be
interpreted as suggesting de novo acquisition of the
organisms from other patients or the hospital en-
vironment, but the fact that most were CC5 lineages
would imply very widespread contamination of the
ward environment and there is no evidence to support
this.
This study has two signiﬁcant limitations. First,
although there is no evidence that this lineage spread
to other units of the hospital, no isolates except for
those presented here were available for comparison.
Second, it was not possible to investigate whether tige-
cycline resistance arose as a consequence of treatment
with other agents owing to the lack of clinical data.
However, given the fact that most isolates were sus-
ceptible to the standard agents used to treat MRSA,
e.g. linezolid and teicoplanin, it is unlikely that the
observed resistance to tigecycline was due to prior
antibiotic treatment.
In conclusion, cases of infection by MRSA strains
resistant to the newest drugs available and their dis-
semination are of major concern. Although the mech-
anisms of resistance remain to be elucidated, this
study has enabled the identiﬁcation of predominant
lineages of MRSA associated with infection and colo-
nization and gives an insight into the emergence of
clinically signiﬁcant resistance. Further studies into
the prevalent MRSA clones in the wider hospital
and region are therefore necessary to determine the
potential disease burden and impact on infection con-
trol practices and antimicrobial usage to limit their
spread.
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